CMT Treatment Report
www.CMTTreatmentReport.com
https://patents.google.com/patent/WO2021211713A1
Treatment of charcot-marie-tooth axonal type 2d using nt-3 gene therapy
Abstract
The present disclosure relates to methods of treating Charcot-Marie-Tooth axonal type 2D (CMT2D) using a rAAV vector for neurotrophin 3 (NT-3) gene therapy.
https://patents.google.com/patent/KR20210117771A/en
Pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease comprising insulin secreted from mesenchymal stem cells or mesenchymal stem cells
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
Abstract
The present invention is in the field of a compound for use as a medicament for treatment of tRNA deficiencies in living cells, a dosage comprising said compound, and an in vivo and in vitro method for treatment of tRNA deficiencies, as well as for prevention, mitigation of symptoms, and regeneration of cells.
